Pycnogenol supplementation as an adjunct treatment for antidepressant-induced sexual dysfunction.

Area of Science:

• Pharmacology
• Neuroscience
• Integrative Medicine

Background:

• Major depressive disorder (MDD) treatment with antidepressants like escitalopram (ESC) can cause adverse events, including sexual dysfunction (SDys).
• Pycnogenol (PYC), a natural antioxidant, anti-inflammatory, and vasodilator, was investigated for its potential to mitigate ESC-induced SDys.

Purpose of the Study:

• To evaluate the effect of Pycnogenol (PYC) on sexual dysfunction (SDys) induced by escitalopram (ESC) in patients with depression.

Main Methods:

• A randomized, parallel, open-label study involving 72 outpatients with depression.
• Participants were divided into two groups: one received ESC plus 50 mg PYC daily for 4 months, the other received ESC only.
• Monthly assessments were conducted over 4 months.

Main Results:

• Escitalopram (ESC) improved depressive symptoms.
• Pycnogenol (PYC) co-treatment significantly attenuated ESC-induced sexual dysfunction (SDys) starting from the first month.
• An increase in heart rate was observed in the Pycnogenol (PYC) group.

Conclusions:

• Pycnogenol (PYC) may reduce escitalopram-induced sexual dysfunction by improving endothelial function through its antioxidant, anti-inflammatory, vasodilatory, and anticoagulant properties.
• The observed increase in heart rate with PYC is likely due to its vasodilatory action and subsequent baroreflex response.
• PYC co-treatment is a potential strategy to manage sexual dysfunction associated with ESC therapy for depression.